GERM vs. GNOM
GERM (Amplify Treatments, Testing and Advancements ETF) and GNOM (Global X Genomics & Biotechnology ETF) are both Health & Biotech Equities funds - GERM tracks the Prime Treatments, Testing and Advancements Index while GNOM tracks the Solactive Genomics Index. Both are passively managed. Over the past year, GERM returned 0.00% vs 54.21% for GNOM. GERM charges 0.68%/yr vs 0.50%/yr for GNOM.
Performance
GERM vs. GNOM - Performance Comparison
Loading charts...
Returns By Period
GERM
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- 0.00%
- 6M
- 0.00%
- 1Y
- 0.00%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
GNOM
- 1D
- 1.99%
- 1M
- 5.82%
- YTD
- 7.81%
- 6M
- 6.65%
- 1Y
- 54.21%
- 3Y*
- -0.94%
- 5Y*
- -10.20%
- 10Y*
- —
GERM vs. GNOM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
GERM Amplify Treatments, Testing and Advancements ETF | 0.00% | 0.00% | 0.00% |
GNOM Global X Genomics & Biotechnology ETF | 7.81% | 18.65% | -9.08% |
GERM vs. GNOM - Sectors Allocation Comparison
Sectors
GERM
GNOM
Healthcare
Financial Services
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
Utilities
-
-
Healthcare
GERM
GNOM
Financial Services
GERM
GNOM
-
Basic Materials
GERM
-
GNOM
-
Communication Services
GERM
-
GNOM
-
Consumer Cyclical
GERM
-
GNOM
-
Consumer Defensive
GERM
-
GNOM
-
Energy
GERM
-
GNOM
-
Industrials
GERM
-
GNOM
-
Real Estate
GERM
-
GNOM
-
Technology
GERM
-
GNOM
Utilities
GERM
-
GNOM
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GERM vs. GNOM — Risk / Return Rank
GERM
GNOM
GERM vs. GNOM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading charts...
Sharpe Ratios by Period
| GERM | GNOM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 2.06 | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.31 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | — | -0.09 | — |
Drawdowns
GERM vs. GNOM - Drawdown Comparison
The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum GNOM drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for GERM and GNOM.
Loading charts...
Drawdown Indicators
| GERM | GNOM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | 0.00% | -75.00% | +75.00% |
Max Drawdown (1Y)Largest decline over 1 year | 0.00% | -18.17% | +18.17% |
Max Drawdown (3Y)Largest decline over 3 years | — | -46.47% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -72.29% | — |
Current DrawdownCurrent decline from peak | 0.00% | -55.45% | +55.45% |
Average DrawdownAverage peak-to-trough decline | 0.00% | -40.55% | +40.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 0.00% | 6.30% | -6.30% |
Volatility
GERM vs. GNOM - Volatility Comparison
The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while Global X Genomics & Biotechnology ETF (GNOM) has a volatility of 8.47%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GERM | GNOM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.00% | 8.47% | -8.47% |
Volatility (6M)Calculated over the trailing 6-month period | 0.00% | 19.44% | -19.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 0.00% | 26.50% | -26.50% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 0.00% | 33.57% | -33.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 0.00% | 34.17% | -34.17% |
GERM vs. GNOM - Expense Ratio Comparison
GERM has a 0.68% expense ratio, which is higher than GNOM's 0.50% expense ratio.
Dividends
GERM vs. GNOM - Dividend Comparison
GERM has not paid dividends to shareholders, while GNOM's dividend yield for the trailing twelve months is around 1.27%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
GERM Amplify Treatments, Testing and Advancements ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GNOM Global X Genomics & Biotechnology ETF | 1.27% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% |
Frequently Asked Questions
GNOM has higher volatility (8.47%) compared to GERM (0.00%). In terms of maximum drawdown, GERM dropped 0.00% vs GNOM's -75.00%.
On 1-year performance, GNOM leads with 54.21% vs 0.00% for GERM. On fees, GNOM is cheaper at 0.50% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 1-year period, GNOM has performed better with a 54.21% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
GNOM is cheaper with a 0.50% expense ratio, compared with 0.68% for GERM.
GNOM has the higher dividend yield at 1.27%, compared with 0.00% for GERM.
GERM tracks Prime Treatments, Testing and Advancements Index, while GNOM tracks Solactive Genomics Index. They also come from different issuers: Amplify and Global X. Their fees differ too: 0.68% for GERM and 0.50% for GNOM.
Find the right allocation for GERM and GNOM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer